| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Helicobacter Infections | 23 | 2025 | 77 | 6.020 |
Why?
|
| Helicobacter pylori | 21 | 2025 | 76 | 4.900 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2025 | 214 | 3.480 |
Why?
|
| Spermatozoa | 7 | 2025 | 29 | 3.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2025 | 175 | 2.290 |
Why?
|
| Lung Neoplasms | 12 | 2025 | 645 | 2.240 |
Why?
|
| Anti-Bacterial Agents | 17 | 2025 | 830 | 2.070 |
Why?
|
| Proton Pump Inhibitors | 9 | 2023 | 95 | 2.070 |
Why?
|
| DNA Methylation | 3 | 2025 | 592 | 1.800 |
Why?
|
| Diethylhexyl Phthalate | 2 | 2023 | 6 | 1.520 |
Why?
|
| Epigenesis, Genetic | 3 | 2025 | 412 | 1.400 |
Why?
|
| Metabolomics | 3 | 2025 | 155 | 1.380 |
Why?
|
| Smoking | 6 | 2024 | 526 | 1.370 |
Why?
|
| Stomach Neoplasms | 7 | 2023 | 207 | 1.350 |
Why?
|
| Middle Aged | 61 | 2025 | 13419 | 1.310 |
Why?
|
| Taiwan | 17 | 2025 | 37 | 1.290 |
Why?
|
| Male | 75 | 2025 | 27435 | 1.260 |
Why?
|
| Lymphocyte Activation | 5 | 2024 | 163 | 1.220 |
Why?
|
| Adult | 54 | 2025 | 14534 | 1.210 |
Why?
|
| Humans | 102 | 2025 | 53230 | 1.190 |
Why?
|
| Acrylamides | 3 | 2024 | 12 | 1.150 |
Why?
|
| Mutation | 7 | 2025 | 1337 | 1.130 |
Why?
|
| Female | 69 | 2025 | 28782 | 1.120 |
Why?
|
| Halogenated Diphenyl Ethers | 2 | 2025 | 4 | 1.110 |
Why?
|
| Aniline Compounds | 2 | 2024 | 48 | 1.050 |
Why?
|
| Phosphoproteins | 2 | 2018 | 117 | 1.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2018 | 202 | 1.040 |
Why?
|
| Menthol | 2 | 2016 | 17 | 0.990 |
Why?
|
| Environmental Exposure | 3 | 2025 | 222 | 0.980 |
Why?
|
| Air Pollutants | 2 | 2025 | 75 | 0.980 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2024 | 52 | 0.980 |
Why?
|
| Bismuth | 3 | 2023 | 11 | 0.930 |
Why?
|
| Clarithromycin | 7 | 2025 | 42 | 0.920 |
Why?
|
| Aged | 46 | 2025 | 10429 | 0.920 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2025 | 1544 | 0.900 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2024 | 7 | 0.900 |
Why?
|
| Polychlorinated Biphenyls | 4 | 2016 | 36 | 0.890 |
Why?
|
| Gastritis | 3 | 2019 | 33 | 0.870 |
Why?
|
| Workplace | 1 | 2025 | 98 | 0.850 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2020 | 67 | 0.840 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2024 | 350 | 0.830 |
Why?
|
| Phthalic Acids | 1 | 2023 | 7 | 0.830 |
Why?
|
| Metabolome | 2 | 2016 | 107 | 0.820 |
Why?
|
| Occupational Exposure | 2 | 2021 | 106 | 0.820 |
Why?
|
| Drug Therapy, Combination | 15 | 2025 | 405 | 0.820 |
Why?
|
| Nicotine | 2 | 2016 | 180 | 0.810 |
Why?
|
| Air Pollution | 2 | 2025 | 49 | 0.800 |
Why?
|
| Doxorubicin | 1 | 2025 | 247 | 0.800 |
Why?
|
| Rats | 10 | 2025 | 3162 | 0.790 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 302 | 0.770 |
Why?
|
| Peptic Ulcer | 4 | 2016 | 15 | 0.760 |
Why?
|
| Flame Retardants | 1 | 2022 | 2 | 0.750 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2020 | 18 | 0.750 |
Why?
|
| Amoxicillin | 8 | 2025 | 24 | 0.750 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1043 | 0.740 |
Why?
|
| Esophagitis | 2 | 2014 | 10 | 0.740 |
Why?
|
| Phosphates | 1 | 2022 | 51 | 0.730 |
Why?
|
| Metronidazole | 6 | 2025 | 32 | 0.720 |
Why?
|
| Animals | 17 | 2025 | 13526 | 0.710 |
Why?
|
| Plasticizers | 1 | 2021 | 1 | 0.690 |
Why?
|
| Carcinoma, Hepatocellular | 7 | 2024 | 212 | 0.680 |
Why?
|
| Pesticides | 1 | 2021 | 21 | 0.680 |
Why?
|
| Prostatic Neoplasms | 2 | 2024 | 401 | 0.670 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 5 | 0.670 |
Why?
|
| Inflammation | 3 | 2025 | 652 | 0.670 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 145 | 0.660 |
Why?
|
| Endocrine Disruptors | 1 | 2021 | 34 | 0.660 |
Why?
|
| Duodenal Ulcer | 5 | 2009 | 12 | 0.650 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 49 | 0.640 |
Why?
|
| Pregnancy | 7 | 2025 | 2608 | 0.640 |
Why?
|
| Aged, 80 and over | 20 | 2025 | 3494 | 0.640 |
Why?
|
| Apoptosis | 6 | 2020 | 1139 | 0.630 |
Why?
|
| Tetracycline | 5 | 2025 | 24 | 0.630 |
Why?
|
| Liver Neoplasms | 7 | 2024 | 346 | 0.630 |
Why?
|
| Case-Control Studies | 9 | 2025 | 1212 | 0.610 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 28 | 0.600 |
Why?
|
| Spermatogenesis | 2 | 2021 | 16 | 0.600 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 65 | 0.590 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 90 | 0.590 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 321 | 0.590 |
Why?
|
| Testis | 3 | 2025 | 74 | 0.580 |
Why?
|
| Proteobacteria | 1 | 2018 | 6 | 0.570 |
Why?
|
| Bacteroidetes | 1 | 2018 | 6 | 0.570 |
Why?
|
| Reactive Oxygen Species | 5 | 2025 | 421 | 0.570 |
Why?
|
| Esophageal and Gastric Varices | 7 | 2017 | 18 | 0.570 |
Why?
|
| Actinobacteria | 1 | 2018 | 11 | 0.560 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2020 | 392 | 0.560 |
Why?
|
| Sperm Motility | 3 | 2025 | 13 | 0.560 |
Why?
|
| Pleural Neoplasms | 1 | 2018 | 8 | 0.560 |
Why?
|
| Cisplatin | 2 | 2019 | 282 | 0.550 |
Why?
|
| Mesothelioma | 1 | 2018 | 16 | 0.550 |
Why?
|
| Gastrointestinal Hemorrhage | 7 | 2017 | 91 | 0.530 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 1222 | 0.530 |
Why?
|
| Peroxidase | 2 | 2008 | 18 | 0.510 |
Why?
|
| Treatment Outcome | 20 | 2024 | 5595 | 0.510 |
Why?
|
| Aneuploidy | 1 | 2016 | 17 | 0.500 |
Why?
|
| Glucuronates | 1 | 2016 | 22 | 0.500 |
Why?
|
| Acetates | 2 | 2014 | 51 | 0.470 |
Why?
|
| Signal Transduction | 10 | 2024 | 1748 | 0.470 |
Why?
|
| Risk Factors | 13 | 2025 | 4017 | 0.450 |
Why?
|
| Semen | 3 | 2023 | 25 | 0.440 |
Why?
|
| Indium | 1 | 2014 | 4 | 0.430 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 319 | 0.420 |
Why?
|
| Fluorocarbons | 2 | 2025 | 65 | 0.410 |
Why?
|
| Environmental Pollutants | 2 | 2025 | 110 | 0.390 |
Why?
|
| Pyrimidines | 3 | 2024 | 205 | 0.380 |
Why?
|
| Testosterone | 2 | 2025 | 142 | 0.380 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 238 | 0.380 |
Why?
|
| Young Adult | 11 | 2019 | 4511 | 0.380 |
Why?
|
| DNA | 4 | 2021 | 535 | 0.370 |
Why?
|
| Tobacco Products | 2 | 2015 | 142 | 0.350 |
Why?
|
| Mass Screening | 2 | 2017 | 362 | 0.350 |
Why?
|
| Particulate Matter | 2 | 2023 | 66 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2024 | 533 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2024 | 233 | 0.350 |
Why?
|
| Genitalia, Male | 2 | 2021 | 16 | 0.340 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 166 | 0.340 |
Why?
|
| Polymorphism, Genetic | 3 | 2015 | 181 | 0.340 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2019 | 110 | 0.320 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 4 | 2018 | 19 | 0.320 |
Why?
|
| Gastric Juice | 1 | 2010 | 6 | 0.320 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2010 | 14 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 868 | 0.300 |
Why?
|
| Prospective Studies | 10 | 2019 | 2411 | 0.300 |
Why?
|
| Anti-Ulcer Agents | 3 | 2005 | 22 | 0.300 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 1723 | 0.300 |
Why?
|
| Life Style | 2 | 2025 | 150 | 0.290 |
Why?
|
| Cohort Studies | 6 | 2020 | 1557 | 0.290 |
Why?
|
| Liver Cirrhosis | 7 | 2017 | 246 | 0.290 |
Why?
|
| Sulfoxides | 2 | 2005 | 22 | 0.290 |
Why?
|
| Benzimidazoles | 2 | 2005 | 50 | 0.280 |
Why?
|
| Incidence | 4 | 2021 | 1085 | 0.280 |
Why?
|
| Cell Line, Tumor | 6 | 2018 | 1470 | 0.280 |
Why?
|
| Gastric Mucosa | 2 | 2007 | 44 | 0.280 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 774 | 0.270 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 1232 | 0.270 |
Why?
|
| Alleles | 2 | 2024 | 277 | 0.260 |
Why?
|
| Renal Dialysis | 2 | 2025 | 196 | 0.250 |
Why?
|
| Liver | 4 | 2023 | 1150 | 0.250 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2025 | 79 | 0.250 |
Why?
|
| Phosphorylation | 3 | 2024 | 533 | 0.240 |
Why?
|
| Drug Therapy | 2 | 2017 | 47 | 0.230 |
Why?
|
| Semiconductors | 1 | 2025 | 2 | 0.230 |
Why?
|
| Transcription Factors | 3 | 2018 | 571 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2024 | 266 | 0.230 |
Why?
|
| Indoles | 2 | 2024 | 280 | 0.220 |
Why?
|
| Sialoglycoproteins | 1 | 2004 | 12 | 0.220 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2019 | 24 | 0.220 |
Why?
|
| Naphthoquinones | 1 | 2004 | 10 | 0.220 |
Why?
|
| Nutritional Status | 1 | 2025 | 148 | 0.220 |
Why?
|
| Mice | 5 | 2023 | 5982 | 0.220 |
Why?
|
| Follow-Up Studies | 12 | 2022 | 2318 | 0.220 |
Why?
|
| Hepatitis B, Chronic | 3 | 2015 | 13 | 0.220 |
Why?
|
| Interleukin-2 | 2 | 2020 | 69 | 0.220 |
Why?
|
| Dimethylformamide | 1 | 2004 | 1 | 0.220 |
Why?
|
| Manufactured Materials | 1 | 2004 | 1 | 0.220 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2025 | 83 | 0.210 |
Why?
|
| Louisiana | 1 | 2024 | 41 | 0.210 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2024 | 3 | 0.210 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2024 | 15 | 0.210 |
Why?
|
| North Carolina | 1 | 2024 | 53 | 0.210 |
Why?
|
| Jurkat Cells | 1 | 2024 | 29 | 0.210 |
Why?
|
| Drug Hypersensitivity | 1 | 2024 | 46 | 0.210 |
Why?
|
| Morpholines | 1 | 2024 | 64 | 0.210 |
Why?
|
| Recurrence | 8 | 2017 | 694 | 0.210 |
Why?
|
| Tyrosine | 1 | 2024 | 92 | 0.210 |
Why?
|
| Interferon-gamma | 2 | 2020 | 174 | 0.210 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2016 | 90 | 0.200 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 371 | 0.200 |
Why?
|
| Alkanesulfonic Acids | 1 | 2023 | 11 | 0.200 |
Why?
|
| Interleukin-6 | 3 | 2015 | 272 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 124 | 0.200 |
Why?
|
| Exanthema | 2 | 2022 | 33 | 0.200 |
Why?
|
| Health Status | 1 | 2025 | 306 | 0.200 |
Why?
|
| Sphincterotomy, Endoscopic | 2 | 2016 | 15 | 0.200 |
Why?
|
| Water | 1 | 2023 | 87 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 180 | 0.200 |
Why?
|
| Severity of Illness Index | 7 | 2012 | 1049 | 0.200 |
Why?
|
| Sex Factors | 4 | 2016 | 747 | 0.200 |
Why?
|
| Flow Cytometry | 4 | 2020 | 400 | 0.190 |
Why?
|
| Lipids | 1 | 2023 | 163 | 0.190 |
Why?
|
| RNA, Messenger | 6 | 2021 | 1133 | 0.190 |
Why?
|
| Retrospective Studies | 11 | 2025 | 6819 | 0.190 |
Why?
|
| Catheterization | 2 | 2016 | 95 | 0.190 |
Why?
|
| Time Factors | 4 | 2019 | 2991 | 0.190 |
Why?
|
| Organophosphates | 1 | 2022 | 5 | 0.190 |
Why?
|
| Endoscopy, Gastrointestinal | 5 | 2012 | 73 | 0.190 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 108 | 0.190 |
Why?
|
| Organophosphorus Compounds | 1 | 2022 | 18 | 0.190 |
Why?
|
| Zinc | 1 | 2022 | 56 | 0.190 |
Why?
|
| Prognosis | 8 | 2025 | 2118 | 0.180 |
Why?
|
| Hydrogen Peroxide | 1 | 2022 | 121 | 0.180 |
Why?
|
| Antigens, Bacterial | 2 | 2016 | 55 | 0.180 |
Why?
|
| Organometallic Compounds | 2 | 2012 | 42 | 0.180 |
Why?
|
| Up-Regulation | 5 | 2014 | 456 | 0.180 |
Why?
|
| Adolescent | 8 | 2017 | 6907 | 0.170 |
Why?
|
| Pesticide Residues | 1 | 2021 | 7 | 0.170 |
Why?
|
| Herbicides | 1 | 2021 | 11 | 0.170 |
Why?
|
| Sigmoidoscopy | 2 | 2014 | 10 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1219 | 0.170 |
Why?
|
| Antiviral Agents | 2 | 2013 | 179 | 0.170 |
Why?
|
| Lymphocytes, Null | 1 | 2020 | 1 | 0.170 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2020 | 5 | 0.170 |
Why?
|
| Antibody Specificity | 1 | 2020 | 36 | 0.170 |
Why?
|
| Paronychia | 1 | 2020 | 1 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 598 | 0.170 |
Why?
|
| Gallstones | 3 | 2009 | 12 | 0.170 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 64 | 0.160 |
Why?
|
| Reproduction | 1 | 2021 | 64 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 42 | 0.160 |
Why?
|
| Pancreatitis | 3 | 2016 | 69 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 109 | 0.160 |
Why?
|
| Rural Population | 1 | 2025 | 596 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 228 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 192 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2004 | 85 | 0.160 |
Why?
|
| Quinolones | 1 | 2020 | 52 | 0.160 |
Why?
|
| MicroRNAs | 2 | 2014 | 397 | 0.160 |
Why?
|
| Bacterial Proteins | 3 | 2016 | 347 | 0.160 |
Why?
|
| Sulfones | 1 | 2019 | 24 | 0.150 |
Why?
|
| Disease Management | 2 | 2021 | 187 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 50 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2020 | 138 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2007 | 128 | 0.150 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 62 | 0.150 |
Why?
|
| Seasons | 1 | 2019 | 92 | 0.150 |
Why?
|
| Gastrectomy | 1 | 2019 | 73 | 0.150 |
Why?
|
| Age Factors | 4 | 2016 | 1136 | 0.150 |
Why?
|
| Body Weight | 1 | 2021 | 524 | 0.150 |
Why?
|
| Length of Stay | 2 | 2019 | 684 | 0.150 |
Why?
|
| Arkansas | 1 | 2025 | 2068 | 0.150 |
Why?
|
| Monocytes | 3 | 2003 | 126 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2018 | 1031 | 0.140 |
Why?
|
| Endoscopy | 3 | 2023 | 128 | 0.140 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2018 | 9 | 0.140 |
Why?
|
| Risk Assessment | 5 | 2016 | 1368 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2019 | 456 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 69 | 0.140 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 214 | 0.130 |
Why?
|
| Feces | 1 | 2018 | 159 | 0.130 |
Why?
|
| Enzyme Activation | 3 | 2008 | 267 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 254 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 579 | 0.130 |
Why?
|
| Pacific Islands | 1 | 2017 | 18 | 0.130 |
Why?
|
| Asia | 1 | 2017 | 24 | 0.130 |
Why?
|
| Epidemiological Monitoring | 1 | 2017 | 15 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 332 | 0.130 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 28 | 0.130 |
Why?
|
| Semen Analysis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Japan | 1 | 2016 | 42 | 0.130 |
Why?
|
| Nadolol | 2 | 2008 | 3 | 0.130 |
Why?
|
| Choledocholithiasis | 1 | 2016 | 13 | 0.120 |
Why?
|
| Dilatation | 1 | 2016 | 28 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 477 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2007 | 1367 | 0.120 |
Why?
|
| Genotype | 3 | 2024 | 563 | 0.120 |
Why?
|
| Caspase 9 | 2 | 2007 | 13 | 0.120 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 81 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 412 | 0.120 |
Why?
|
| Caspase 3 | 2 | 2007 | 92 | 0.120 |
Why?
|
| Alcohol Drinking | 2 | 2009 | 241 | 0.120 |
Why?
|
| Lipopolysaccharides | 4 | 2004 | 203 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 266 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 1925 | 0.120 |
Why?
|
| Esophagitis, Peptic | 1 | 2015 | 4 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2015 | 1569 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1099 | 0.110 |
Why?
|
| Adenosine Diphosphate | 2 | 2004 | 20 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 2 | 2015 | 89 | 0.110 |
Why?
|
| P-Selectin | 2 | 2004 | 27 | 0.110 |
Why?
|
| National Health Programs | 1 | 2014 | 19 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 44 | 0.110 |
Why?
|
| Superoxides | 1 | 2014 | 46 | 0.110 |
Why?
|
| Leukocytes | 2 | 2004 | 58 | 0.110 |
Why?
|
| Cysteine Endopeptidases | 1 | 2014 | 64 | 0.110 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2014 | 22 | 0.100 |
Why?
|
| Intestinal Polyps | 1 | 2014 | 7 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 55 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2007 | 228 | 0.100 |
Why?
|
| Models, Animal | 1 | 2014 | 233 | 0.100 |
Why?
|
| Hysterectomy | 1 | 2014 | 91 | 0.100 |
Why?
|
| Dobutamine | 2 | 2003 | 16 | 0.100 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2013 | 9 | 0.100 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2003 | 39 | 0.100 |
Why?
|
| Chemokine CCL2 | 2 | 2003 | 66 | 0.100 |
Why?
|
| Interferons | 1 | 2013 | 39 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2012 | 185 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 205 | 0.100 |
Why?
|
| Chromatin | 1 | 2014 | 145 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1112 | 0.100 |
Why?
|
| ROC Curve | 2 | 2012 | 246 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2014 | 123 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 139 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2012 | 6 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1517 | 0.100 |
Why?
|
| Quality Control | 1 | 2013 | 98 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 138 | 0.090 |
Why?
|
| Autophagy | 1 | 2014 | 199 | 0.090 |
Why?
|
| DNA Damage | 1 | 2014 | 309 | 0.090 |
Why?
|
| Cesarean Section | 1 | 2014 | 158 | 0.090 |
Why?
|
| Blood Platelets | 2 | 2004 | 247 | 0.090 |
Why?
|
| Dioxins | 1 | 2012 | 12 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2012 | 29 | 0.090 |
Why?
|
| Benzofurans | 1 | 2012 | 19 | 0.090 |
Why?
|
| Interleukins | 1 | 2012 | 34 | 0.090 |
Why?
|
| Gene Expression Regulation | 4 | 2015 | 1003 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 233 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 333 | 0.090 |
Why?
|
| Spleen | 1 | 2012 | 166 | 0.090 |
Why?
|
| Mortality | 1 | 2012 | 98 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 291 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2013 | 411 | 0.080 |
Why?
|
| Transcriptome | 1 | 2014 | 367 | 0.080 |
Why?
|
| Gastroesophageal Reflux | 1 | 2011 | 51 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 89 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 487 | 0.080 |
Why?
|
| Esophagoscopy | 2 | 2017 | 29 | 0.080 |
Why?
|
| Endoscopy, Digestive System | 1 | 2011 | 51 | 0.080 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2024 | 13 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 445 | 0.080 |
Why?
|
| Guanine | 2 | 2013 | 39 | 0.080 |
Why?
|
| Social Class | 1 | 2011 | 97 | 0.080 |
Why?
|
| Hepatic Artery | 2 | 2024 | 21 | 0.080 |
Why?
|
| Educational Status | 1 | 2011 | 229 | 0.080 |
Why?
|
| Areca | 1 | 2009 | 1 | 0.080 |
Why?
|
| Cell Line | 4 | 2006 | 1016 | 0.080 |
Why?
|
| Prevalence | 2 | 2011 | 1034 | 0.080 |
Why?
|
| Gallbladder Neoplasms | 1 | 2009 | 7 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2014 | 819 | 0.080 |
Why?
|
| Ligation | 4 | 2017 | 63 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2014 | 441 | 0.080 |
Why?
|
| Logistic Models | 2 | 2009 | 947 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2007 | 58 | 0.070 |
Why?
|
| Esophageal Achalasia | 1 | 2009 | 8 | 0.070 |
Why?
|
| Endotoxins | 1 | 2009 | 23 | 0.070 |
Why?
|
| Albumins | 1 | 2009 | 29 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2009 | 717 | 0.070 |
Why?
|
| Peritonitis | 1 | 2009 | 24 | 0.070 |
Why?
|
| Somatostatin | 1 | 2008 | 27 | 0.070 |
Why?
|
| Intestinal Mucosa | 2 | 2007 | 229 | 0.070 |
Why?
|
| Isosorbide Dinitrate | 1 | 2008 | 1 | 0.070 |
Why?
|
| B-Cell Activating Factor | 1 | 2008 | 3 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2008 | 32 | 0.070 |
Why?
|
| Adenomyoma | 1 | 2008 | 2 | 0.070 |
Why?
|
| Jejunal Neoplasms | 1 | 2008 | 4 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2009 | 133 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 489 | 0.070 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 90 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 108 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 867 | 0.070 |
Why?
|
| Models, Biological | 2 | 2008 | 737 | 0.070 |
Why?
|
| DNA Primers | 2 | 2004 | 202 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 55 | 0.060 |
Why?
|
| Interleukin-8 | 2 | 2005 | 85 | 0.060 |
Why?
|
| Chemotaxis | 2 | 2003 | 21 | 0.060 |
Why?
|
| Steroid 11-beta-Hydroxylase | 1 | 2006 | 1 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2005 | 726 | 0.060 |
Why?
|
| Membranes, Artificial | 1 | 2025 | 15 | 0.060 |
Why?
|
| Animals, Newborn | 1 | 2007 | 357 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2008 | 150 | 0.060 |
Why?
|
| Gastroscopy | 1 | 2005 | 21 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 627 | 0.060 |
Why?
|
| Ketotifen | 1 | 2005 | 2 | 0.060 |
Why?
|
| Leukotriene Antagonists | 1 | 2005 | 5 | 0.060 |
Why?
|
| Histamine H1 Antagonists | 1 | 2005 | 9 | 0.060 |
Why?
|
| Adenine | 1 | 2005 | 29 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 505 | 0.060 |
Why?
|
| Genes, Bacterial | 1 | 2005 | 51 | 0.060 |
Why?
|
| Quinolines | 1 | 2005 | 44 | 0.060 |
Why?
|
| Chemokines | 1 | 2005 | 78 | 0.060 |
Why?
|
| Diet | 1 | 2009 | 610 | 0.060 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2005 | 34 | 0.060 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2024 | 4 | 0.060 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2004 | 17 | 0.060 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 8 | 0.060 |
Why?
|
| ABO Blood-Group System | 1 | 2004 | 16 | 0.060 |
Why?
|
| Mucous Membrane | 2 | 2019 | 32 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 949 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2004 | 17 | 0.060 |
Why?
|
| Cytochromes c | 1 | 2004 | 28 | 0.060 |
Why?
|
| Anesthesia, Inhalation | 1 | 2004 | 12 | 0.050 |
Why?
|
| Midazolam | 1 | 2004 | 37 | 0.050 |
Why?
|
| Anesthetics, Intravenous | 1 | 2004 | 22 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2004 | 30 | 0.050 |
Why?
|
| Methyl Ethers | 1 | 2004 | 17 | 0.050 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2024 | 12 | 0.050 |
Why?
|
| Gene Expression | 1 | 2007 | 618 | 0.050 |
Why?
|
| Formamides | 1 | 2004 | 4 | 0.050 |
Why?
|
| Chromatography, Gas | 1 | 2004 | 15 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2025 | 274 | 0.050 |
Why?
|
| Platelet Aggregation | 1 | 2004 | 77 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2004 | 103 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 53 | 0.050 |
Why?
|
| Membrane Potentials | 1 | 2004 | 100 | 0.050 |
Why?
|
| Urine | 1 | 2004 | 26 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 55 | 0.050 |
Why?
|
| Caspases | 1 | 2004 | 101 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 6 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2004 | 146 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2004 | 6 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2005 | 232 | 0.050 |
Why?
|
| Immunotoxins | 1 | 2004 | 6 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 73 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2004 | 11 | 0.050 |
Why?
|
| Tranexamic Acid | 1 | 2004 | 14 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 36 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 122 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2003 | 12 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 130 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2003 | 4 | 0.050 |
Why?
|
| Decanoic Acids | 1 | 2023 | 1 | 0.050 |
Why?
|
| Sulfonic Acids | 1 | 2023 | 1 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 92 | 0.050 |
Why?
|
| Caprylates | 1 | 2023 | 5 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 170 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 152 | 0.050 |
Why?
|
| Lidocaine | 1 | 2003 | 46 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 452 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 175 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 289 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 77 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2004 | 226 | 0.050 |
Why?
|
| Vitamin D | 1 | 2023 | 91 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2023 | 61 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2023 | 154 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 975 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 245 | 0.050 |
Why?
|
| Platelet Count | 2 | 2012 | 68 | 0.050 |
Why?
|
| Amphetamines | 1 | 2002 | 26 | 0.050 |
Why?
|
| Phencyclidine | 1 | 2002 | 32 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 370 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2002 | 46 | 0.040 |
Why?
|
| Probability | 3 | 2009 | 171 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2001 | 60 | 0.040 |
Why?
|
| Parkinsonian Disorders | 1 | 2001 | 14 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 351 | 0.040 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2002 | 54 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2001 | 76 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 131 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 79 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 253 | 0.040 |
Why?
|
| Asthma | 1 | 2005 | 319 | 0.040 |
Why?
|
| Betaxolol | 1 | 2020 | 1 | 0.040 |
Why?
|
| Antacids | 1 | 2020 | 12 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 171 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2020 | 25 | 0.040 |
Why?
|
| Mitochondria | 1 | 2004 | 446 | 0.040 |
Why?
|
| Motivation | 1 | 2022 | 287 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 138 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 880 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 2019 | 22 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 934 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 146 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 237 | 0.040 |
Why?
|
| Neutrophils | 1 | 2020 | 153 | 0.040 |
Why?
|
| Reference Values | 2 | 2012 | 311 | 0.040 |
Why?
|
| Cell Movement | 3 | 2003 | 279 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 76 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 502 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 206 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 630 | 0.030 |
Why?
|
| Calcium | 3 | 2003 | 373 | 0.030 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2017 | 11 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2017 | 25 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 198 | 0.030 |
Why?
|
| Acute Disease | 2 | 2008 | 393 | 0.030 |
Why?
|
| Cholangiography | 1 | 2016 | 11 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 75 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 31 | 0.030 |
Why?
|
| Connective Tissue Diseases | 1 | 2016 | 20 | 0.030 |
Why?
|
| Brain | 2 | 2002 | 1350 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 84 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 647 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2016 | 84 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2016 | 124 | 0.030 |
Why?
|
| Smoke | 1 | 2015 | 18 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2015 | 28 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 89 | 0.030 |
Why?
|
| S Phase | 1 | 2014 | 20 | 0.030 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2014 | 18 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 189 | 0.030 |
Why?
|
| Mitomycin | 1 | 2014 | 19 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 88 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2014 | 59 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2014 | 43 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 59 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 109 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 49 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 109 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2014 | 122 | 0.030 |
Why?
|
| Alcoholism | 1 | 2017 | 242 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 134 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 83 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2014 | 232 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 128 | 0.030 |
Why?
|
| Appendectomy | 1 | 2014 | 36 | 0.030 |
Why?
|
| Depression, Chemical | 2 | 2003 | 12 | 0.030 |
Why?
|
| Pelvis | 1 | 2014 | 66 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2014 | 74 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 190 | 0.030 |
Why?
|
| Abdomen | 1 | 2014 | 71 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 181 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 20 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 127 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 90 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 465 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 742 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2013 | 118 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 112 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 1180 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 620 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 587 | 0.020 |
Why?
|
| Elasticity | 1 | 2012 | 19 | 0.020 |
Why?
|
| Albuterol | 2 | 2003 | 54 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 759 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 118 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2013 | 188 | 0.020 |
Why?
|
| Ribavirin | 1 | 2012 | 17 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 226 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2012 | 47 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2012 | 53 | 0.020 |
Why?
|
| Dopamine | 2 | 2003 | 167 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 118 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 95 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 75 | 0.020 |
Why?
|
| Cerebral Cortex | 2 | 2002 | 194 | 0.020 |
Why?
|
| Hyperamylasemia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 66 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 107 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 211 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2008 | 85 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2009 | 96 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 466 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 168 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2008 | 187 | 0.020 |
Why?
|
| Duodenum | 1 | 2007 | 34 | 0.020 |
Why?
|
| Bilirubin | 1 | 2007 | 43 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2009 | 233 | 0.020 |
Why?
|
| Esophagus | 1 | 2007 | 83 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2008 | 327 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 501 | 0.020 |
Why?
|
| Flavones | 1 | 2006 | 5 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2006 | 24 | 0.010 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2006 | 30 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2006 | 33 | 0.010 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2006 | 23 | 0.010 |
Why?
|
| Duodenoscopy | 1 | 2005 | 2 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2006 | 128 | 0.010 |
Why?
|
| Chemokine CCL17 | 1 | 2005 | 1 | 0.010 |
Why?
|
| Chemokine CCL22 | 1 | 2005 | 1 | 0.010 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2005 | 9 | 0.010 |
Why?
|
| Chemokines, CC | 1 | 2005 | 8 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 203 | 0.010 |
Why?
|
| Sulfides | 1 | 2005 | 29 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2005 | 20 | 0.010 |
Why?
|
| Cyclopropanes | 1 | 2005 | 27 | 0.010 |
Why?
|
| Acids | 1 | 2005 | 9 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2005 | 89 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 359 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 97 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2004 | 5 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2007 | 282 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 169 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2005 | 71 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 2004 | 12 | 0.010 |
Why?
|
| Hemostasis, Surgical | 1 | 2004 | 11 | 0.010 |
Why?
|
| Hepatitis C Antibodies | 1 | 2004 | 19 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 173 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2004 | 15 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2004 | 26 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 107 | 0.010 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 2004 | 3 | 0.010 |
Why?
|
| Virulence Factors | 1 | 2005 | 79 | 0.010 |
Why?
|
| Omeprazole | 1 | 2004 | 17 | 0.010 |
Why?
|
| Dizziness | 1 | 2004 | 13 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 563 | 0.010 |
Why?
|
| Chemokine CCL4 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 2003 | 12 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 93 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 638 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 729 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 659 | 0.010 |
Why?
|
| Dopamine Antagonists | 1 | 2002 | 22 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2002 | 57 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 89 | 0.010 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2001 | 5 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2001 | 10 | 0.010 |
Why?
|
| Neostriatum | 1 | 2001 | 9 | 0.010 |
Why?
|
| Neoplasms | 1 | 2012 | 1334 | 0.010 |
Why?
|
| Glycine | 1 | 2002 | 75 | 0.010 |
Why?
|
| Cell Death | 1 | 2002 | 171 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 233 | 0.010 |
Why?
|
| United States | 1 | 2012 | 5409 | 0.010 |
Why?
|
| Cerebellum | 1 | 2001 | 121 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 607 | 0.010 |
Why?
|
| Child | 1 | 2005 | 7379 | 0.010 |
Why?
|